.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AA01_Cyclophosphamide.Cyclophosphamide_1 .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AA01_Cyclophosphamide.Cyclophosphamide_1| name: | Cyclophosphamide_1 |
| ATC code: | L01AA01_1 | route: | oral |
| n-compartments | 1 |
Cyclophosphamide is an alkylating agent used in cancer chemotherapy and for immune modulation in some autoimmune diseases. It is approved and clinically in use.
Pharmacokinetics of cyclophosphamide in healthy adult volunteers after oral administration.
Veluvolu, S, et al., & Wittenburg, L (2023). Fractionated oral dosing and its effect on cyclophosphamide pharmacokinetics in dogs with high-grade multicentric lymphoma. Veterinary and comparative oncology 21(1) 20–27. DOI:10.1111/vco.12856 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36057542
Hadjibabaie, M, et al., & Sadrai, S (2011). Population pharmacokinetics of oral high-dose busulfan in adult patients undergoing hematopoietic stem cell transplantation. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 19(3) 216–223. PUBMED:https://pubmed.ncbi.nlm.nih.gov/22615660
Tran, HT, et al., & Chan, KW (2000). Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone marrow transplantation 26(5) 463–470. DOI:10.1038/sj.bmt.1702561 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11019834